top of page
Clinical background image.png

Clinical Trials Guide

LATEST ON CLINICAL TRIALS

DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) • Dr. Aman Chauhan
08:26

DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) • Dr. Aman Chauhan

Boehringer Ingelheim is sponsoring a phase 1 study, a phase 1 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific or “BiTE”) that may help the immune system fight cancer. The study is in adults with extensive stage small cell lung cancer who have previously received platinum-based chemotherapy and are eligible to receive topotecan treatment. The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with topotecan, a chemotherapy treatment called topoisomerase 1 inhibitor, that works by blocking a chemical (topoisomerase 1) that helps cancer cells repair and separate DNA when they divide. Participants get BI 764532 and topotecan as infusions into a vein. As an alternative, topotecan may also be taken orally (tablets). Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials.

Browse by Trial: 

​

By type of disease or treatment
Browse by trial
Clinical Trials.png

Clinical Trials Guide

Browse by Type of Disease or Treatment: 

Pancreatic NET (PNET)
Click Here
Lung/Bronchial NETs
Click Here
G3 Neuroendocrine Neoplasms (NEN) or High Grade
Click Here
Immunotherapy
Click Here
NIH/NCI Natural History Study for Neuroendocrine Neoplasms
Click Here
Additional Resources
Click Here
Gastrointestinal (GI) NETs
Click Here
Pheochromocytoma/ Paraganglioma
Click Here
Peptide Receptor Radionuclide Therapy (PRRT)
Click Here
Somatostatin Analogue (SSA)
Click Here

UNDERSTANDING CLINICAL TRIALS

Finding and learning more about relevant neuroendocrine cancer clinical

trials may feel overwhelming. While comprehensive databases are available

to search for trials, it may be difficult to understand whether a trial is right for you. 

​

Our goal is to offer a resource with key, open clinical trials for those with neuroendocrine cancer (aka, neuroendocrine neoplasm or NEN, including neuroendocrine tumor or NET and neuroendocrine carcinoma or NEC). We hope this information will help you better

understand clinical trials and empower you to discuss them with your medical team.

 

You may browse the Clinical Trials Guide in the following ways:

 

 

When exploring the Clinical Trials Guide, you will find a description of each trial and contact information. Many also include a video of a NET expert describing the trial. The videos explain the study and who is eligible to participate.

 

You can consider clinical trials at any time during your NET journey. Options range from first-line treatments for those newly diagnosed to novel treatments for those who have already had multiple treatments. For more information on how your involvement may benefit you and the NET community, read Why Participate in Clinical Trials.

Clinical Trials - LACNETS - Infographic (1000 × 2700 px).png
Ancora

Ancora.ai

Ancora.ai is a neuroendocrine tumor clinical trial finder for patients and physicians developed by Ancora.ai and NorCalCarciNET. Ancora allows you to do a personalized search, filter and export results, and if interested, Ancora's patient team can help connect you to a trial site to begin the evaluation process. It's free and easy to use. Click here to access Ancora.ai >>

Ancora.JPG

DISCLAIMER:

  • This information is for educational purposes only. LACNETS encourages you to discuss your individual care and treatment options with your medical team. LACNETS does not endorse any particular trial or treatment. This is not a complete list of available NET trials nor is it intended to be. For comprehensive information about available clinical trials, go to ClinicalTrials.Gov.

bottom of page